Tuesday 5th December 7.30-8.30am at Oxford Examination School
SHE STARTED IN OXFORD – BREAKFAST WITH FOUR INSPIRATIONAL SPEAKERS. 5th December, 7.30-8.30am at Oxford Examination Schools
Oxford has always led the way in education, research and innovation. Unsurprisingly, thousands of influential leaders have begun their journey here. The list of famous Oxonians includes 51 Nobel Prize winners, 27 British Prime Ministers and countless CEOs, all of whom have disrupted their field, changing the status quo.
We have asked four successful women who began their journeys in Oxford to share their stories with us over breakfast. Join us for what will surely be an inspirational occasion. Just imagine the conversation over a coffee and croissant!
Shona Tatchell, CEO and Founder, Halotrade
Shona is the CEO and Founder of Halotrade, a blockchain enabled Fintech start up focussed on the delivery of sustainable supply chain financing. Formerly Head of Innovation for Trade & Working Capital at Barclays, working in partnership with emerging technology companies which will shape the future of the global Trade business.
Shona was a Director with Barclays for 6 years, and was previously Global Head of Financial Institutions Trade, delivering trade finance, trade services and risk mitigation solutions to bank and non-bank institutional clients globally. She joined from HSBC where she was a senior manager in the European Structured Trade and Advisory team within Global Trade and Supply Chain.
She began her career with The Chase Manhattan Bank, graduating from the European Credit Training Programme and joined Chase’s Trade Finance team, where she spent 13 years working in London, the Middle East and Singapore where she headed Chase’s Trade business.
Shona owned her own successful hotel business in the Highlands of Scotland for several years after leaving Asia, before returning to banking in 2008.
Shona holds a Bachelor of Arts and a Master of Arts in Modern Languages (French and German) from the University of Oxford (St Edmund Hall).
Dr Emma Sceats, CEO, CN Bio Innovations
Dr Emma Sceats is the Chief Executive Officer of CN Bio Innovations, a world leader in Organs-on-Chips, sophisticated devices that mimic the structure and function of human organs in the laboratory.
CN Bio’s Organs-on-Chips are dramatically improving testing methodologies for drugs, cosmetics and other chemicals. Under Emma’s leadership CN Bio has secured partnerships with several global pharma and consumer goods companies, as well as entering into a trailblazing partnership with the US Food & Drug Administration (FDA) to evaluate use of the company’s organ mimics in drug development.
Dr Sceats was responsible for licensing of key Organ-on-Chip patents from the Massachusetts Institute of Technology in 2012, and in the same year co-wrote with collaborators at MIT a successful application to the US Department of Defence resulting in a $26M contract to develop a human Body-on-a-Chip.
Most recently, she has raised more than £6M for CN Bio and led the licensing of a Hepatitis B drug discovery programme from global pharmaceutical company Bristol Myers Squibb.
Prior to joining CN Bio, Dr Sceats served as a licensing manager at Oxford University Innovation, licensing and commercialising a diverse portfolio of IP and software developed at the University.
Dr Sceats was a Presidential scholar (Chemistry) at MIT and a graduate scholar at the University of Oxford. Dr Sceats was an inaugural recipient of Innovate UK’s Women in Innovation award in 2017.
Professor Trudie Lang, Professor of Global Health and Director of The Global Health Network
Global Health and Director of The Global Health Network at the University of Oxford. Her role has seen her build a global network of health workers and research staff across the globe using the latest innovations in digital technology and data management to share skills, best practice and developing skills and capacity to reduce the mortality rates caused by the most burdensome diseases that affect these regions.
Having spent over 10 years in industry – at Syntex Pharmaceuticals (1992-94) and GlaxoSimithKline (1994-2004) – Trudie’s pioneering approach combines perspectives from business and academia to address the most critical issues of global heath. Her work provides a startling new insight into how economic potential might be unlocked by radically rethinking global heath practices.
In 2002 Trudie was seconded to the World Health Organisation, building upon a network of collaborating partners that now extends to the US Center for Disease Control, Harvard University, The London and Liverpool School of Tropical Medicine, The University of Capetown, Institut Pasteur, the European Medicines Agency and the Gates Foundation.
Prior to joining The Global Health Network in 2008, Trudie spent two years as Head of Clinical Trials for the Kemri-Wellcome Programme in Kilfi Kenya.
To date she has published over 58 articles in highly respected journals including Science, Lancet, British Medical Journal and the New England Journal of Medicine.
Laura Ferguson, UK Director, Capital Cell
Laura is UK Director of Capital Cell, Europe’s first equity crowdfunding platform specialised in life sciences.
Capital Cell was established in Spain in 2015, and in August 2017 had successfully funded 14 campaigns to raise over €4.2M directly on the platform. No company has failed so far, two have gone on to secure series A funding, and one has given investors a partial exit at 2x return. Laura joined Capital Cell in 2016, and led the funding round and launch of Capital Cell UK (www.capitalcell.co.uk).
Capital Cell has a unique method of conducting multi-level due diligence on the companies it lists, including obtaining ‘Fast Market Feedback’ from the BioExpert Network- a community of >700 experts in life science and life science commercialisation. The feedback from the network is both given to the entrepreneurs in full to help them develop their pitch/ business model, and is listed alongside the campaign information on the Capital Cell site for potential investors to see (www.bioexpertnetwork.com).
Before Joining Capital Cell Laura was a Research Fellow at Christ Church Oxford in molecular evolutionary genetics. She has a PhD in the same subject from Cambridge, a research Masters in cancer stem cells from Bristol, and a biology degree with additional honours in the History and Philosophy of Science from Oxford. Her PhD was on the genetic basis of evolution in butterfly wing pattern mimicry.
Having spent quite a bit of time around Oxbridge as an academic, Laura considers it an absolute privilege to be able to stay at the cutting edge of science through her work with Capital Cell. Laura lives just outside Cambridge with her husband and three boys.
This event is run in conjunction with Innovation Forum Conference, a C-level conference gathering top leaders from industry, academia and government and mixing them with early stage ventures investors and researchers. To find out more about the conference and register visit: http://inno-forum.org/if2017/.